References
- Headache classification committee of the international headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. doi:10.1177/0333102417738202
- Silberstein SD. Preventive migraine treatment. Continuum. 2015;21(4 Headache):973–989. doi:10.1212/CON.0000000000000199
- Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician. 2019;99(1):17–24.
- Ailani J, Burch RC, Robbins MS. the Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–1039. doi:10.1111/head.14153
- Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):56. doi:10.1186/s10194-023-01594-1
- Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets. 2020;24(2):91–100. doi:10.1080/14728222.2020.1724285
- Muddam MR, Obajeun OA, Abaza A, et al. Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: a Systematic Review. Cureus. 2023;15(9):e45560. doi:10.7759/cureus.45560
- Yang C-P, Liang C-S, Chang C-M, et al. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: a Systematic Review and Meta-analysis. JAMA Network Open. 2021;4(10):e2128544–e2128544. doi:10.1001/jamanetworkopen.2021.28544
- Pfizer Inc. Nurtec ODT (rimegepant) Prescribing information. Available from: https://labeling.pfizer.com/ShowLabeling.aspx?id=19036. Accessed June 6, 2023.
- Pfizer. Vydura (rimegepant) Prescribing Information. Available from: https://www.pfizerpro.co.uk/medicine/vydura. Accessed July 20, 2023.
- Lipton RB, Blumenfeld A, Jensen CM, et al. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: pooled results from three Phase 3 randomized clinical trials. Cephalalgia. 2023;43(2):3331024221141686. doi:10.1177/03331024221141686
- Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–745. doi:10.1016/S0140-6736(19)31606-X
- ClinicalTrials.gov. Study NCT03235479. Available from: https://clinicaltrials.gov/study/NCT03235479. Accessed July 26, 2023.
- ClinicalTrials.gov. Study NCT03237845. Available from: https://clinicaltrials.gov/study/NCT03237845. Accessed July 26, 2023.
- ClinicalTrials.gov. Study NCT03461757. Available from: https://clinicaltrials.gov/study/NCT03461757. Accessed July 26, 2023.
- Croop R, Berman G, Kudrow D, et al. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 2024;44. doi:10.1177/03331024241232944
- Berman G, Croop R, Kudrow D, et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020;60(8):1734–1742. doi:10.1111/head.13930